ChromaDex (CDXC) Projected to Post Earnings on Wednesday

ChromaDex (NASDAQ:CDXC) is anticipated to release its earnings data before the market opens on Wednesday, March 5th. Analysts expect ChromaDex to post earnings of $0.02 per share and revenue of $26.51 million for the quarter.

ChromaDex Trading Down 1.1 %

NASDAQ:CDXC opened at $5.44 on Wednesday. ChromaDex has a 12 month low of $1.51 and a 12 month high of $7.97. The firm’s 50 day moving average is $5.62 and its 200 day moving average is $5.00. The stock has a market capitalization of $415.52 million, a PE ratio of 544.54 and a beta of 2.21.

Analysts Set New Price Targets

CDXC has been the topic of several research reports. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday. HC Wainwright boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Finally, Roth Mkm increased their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

Insider Buying and Selling at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares in the company, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.